Mallinckrodt Plc's Revenue in the fiscal year 2024 $ 1,083.40 millions
Mallinckrodt Plc's Revenue in the fiscal year 2021 $ 2,208.80 millions
Mallinckrodt Plc's Revenue in the fiscal year 2020 $ 2,213.40 millions
Mallinckrodt Plc's Revenue in the fiscal year 2019 $ 3,162.50 millions
Mallinckrodt Plc's Revenue in the fiscal year 2018 $ 3,215.60 millions
MNKKQ Revenue second quarter 2022 Y/Y Growth Comment
Mallinckrodt Plc achieved in the second quarter 2022, above Company average Revenue improvement of 5.36% year on year, to $ 517.20 millions.
Looking into second quarter 2022 results within Major Pharmaceutical Preparations industry 106 other companies have achieved higher Revenue growth. While Mallinckrodt Plc' s Revenue increase of 5.36% ranks overall at the positon no. 2046 in the second quarter 2022.
Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022
Mallinckrodt Plc's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
319.4 %
10.67 %
-74.99 %
(Sep 25 2020)
MNKKQ's II. Quarter Q/Q Revenue Comment
Mallinckrodt Plc achieved in the II. Quarter 2022 below company average Revenue increase of 6.62% quarter on quarter, to $ 517.20 millions.
II. Quarter 2022 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -17.8% in the II. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 111 other companies have achieved higher Revenue quarter on quarter growth. While Mallinckrodt Plc's Revenue growth quarter on quarter, overall rank is 1424.
Mallinckrodt Plc achieved in the II. Quarter 2022 below company average Revenue increase of 6.62% quarter on quarter, to $ 517.20 millions.
II. Quarter 2022 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -17.8% in the II. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 111 other companies have achieved higher Revenue quarter on quarter growth. While Mallinckrodt Plc's Revenue growth quarter on quarter, overall rank is 1424.
Mallinckrodt Plc's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 16 2022)
12 Months Ending (Apr 01 2022)
12 Months Ending (Dec 31 2021)
12 Months Ending (Sep 24 2021)
12 Months Ending (Jun 25 2021)
Cumulative Revenue 12 Months Ending
$ 1,979.00
$ 2,141.70
$ 2,208.80
$ 2,294.40
$ 2,485.50
Y / Y Revenue Growth (TTM)
-20.38 %
1.71 %
-0.21 %
-1.76 %
4.39 %
Year on Year Revenue Growth Overall
Ranking
# 3129
# 3493
# 3498
# 2356
# 2052
Seqeuential Revenue Change (TTM)
-7.6 %
-3.04 %
-3.73 %
-7.69 %
18.04 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2046
# 3159
# 3167
# 2604
# 2530
Cumulative Revenue growth Comment
For the 12 months ended Jun 16 2022 Mallinckrodt Plc reported a fall in Revenue by -20.38% year on year, to $1,979 millions, compare to the 1.71% growth at Apr 01 2022.
In the Healthcare sector 441 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3129, from total ranking in previous quarter at 3493.
For the 12 months ended Jun 16 2022 Mallinckrodt Plc reported a fall in Revenue by -20.38% year on year, to $1,979 millions, compare to the 1.71% growth at Apr 01 2022.
In the Healthcare sector 441 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3129, from total ranking in previous quarter at 3493.
About Mallinckrodt Plc Revenue Growth Rates (MNKKQ), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
9.32%